Clinical Trial

Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this research study is to test the safety and effectiveness of Seleno-L Methionine (SLM) when combined with the standard dose and schedule of Axitinib and Pembrolizumab in patients who have locally advanced or metastatic clear cell renal cell carcinoma (ccRCC).
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2022-05-02; most recent amendment 2025-12-03.
Status change: Recruiting → Active, Not Recruiting 2025-12-03
Status change: Not Yet Recruiting → Recruiting 2022-09-19
Trial Details
NCT Number NCT05363631
Lead Sponsor Mohammed Milhem
Collaborators: University of Iowa
Conditions Clear Cell Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic
Enrollment 55 participants
Start Date 2022-09-19
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-10